Stopping Statins After 70 May Be Safer Than Expected, but There's a Catch - Science Daily

For many adults over 70, the daily ritual of taking a statin to prevent a first heart attack or stroke has been considered a part of healthy aging.

But a new study presented at the American Heart Association’s Scientific Sessions 2026 in Chicago suggests that this preventive approach might be more complex than the medical community previously assumed.

The research, which tracked 1,880 adults across 24 medical centers in Switzerland, France, and the Netherlands, found that participants who stopped taking statins did not experience a statistically significant increase in cardiovascular events like heart attacks or strokes over a two-year period. For those looking to simplify their medication regimen, these findings offer a moment of clinical observation.

However, the data carries a significant caveat that prevents a simple “stop or go” recommendation. While the two-year outlook appeared stable, researchers observed a diverging trend when they extended the follow-up period to four years.

In that longer window, 12.7% of those who stopped their medication experienced a heart attack, stroke, or death, compared to 9.2% of those who stayed the course. The study highlights that the protective benefits of statins may accumulate in ways that only become visible over time.

The Complexity of Preventive Care in Later Life

The study specifically targeted adults aged 70 and older who had no history of heart disease but managed at least two chronic conditions. This group represents a significant slice of the population, as an estimated 25% of American adults have elevated levels of low-density lipoprotein-cholesterol (LDL-C).

By focusing on “primary prevention”—stopping a first event before it happens—the researchers aimed to clarify whether the risks of polypharmacy in older age outweigh the benefits of cholesterol management.

“While the Association’s recent joint guideline recommends lifestyle and potentially medication for people with high LDL-C at younger ages to reduce the risk of heart attack and stroke, recent studies question the health benefits of continuing statins in the later decades of life.”

said study author Rita F. Redberg, M.D., M.Sc., FAHA, professor of cardiology and the Araxe Vilensky Endowed Chair in Cardiology at the University of California, San Francisco School of Medicine.

Dr. Redberg said that while earlier, smaller studies assessed the safety of discontinuing statins for primary prevention at age 70 and later and found no difference in mortality, the increased duration and scale of this recent trial provide a more nuanced picture of the risks involved in discontinuation.

Weighing the Individual Stakes

The researchers looked for improvements in quality of life, muscle pain, falls, and sarcopenia among those who stopped their statins. Stopping the pills did not lead to measurable improvements in these outcomes. Quality of life, muscle discomfort, falls, and muscle wasting were similar in both groups.

It is worth noting that about 14% of the participants switched from their assigned treatment approach during the study. Even after accounting for these shifts, the core findings held steady: the short-term safety of stopping is real, but the long-term protection provided by the medication remains a factor that cannot be ignored.

For a patient, this creates a medical dilemma. The American Heart Association’s 2026 joint guideline on dyslipidemia continues to emphasize that there is no one-size-fits-all answer here.

The results underscore that this is not a scenario where a general policy shift is appropriate. Instead, the data points toward a need for intensified communication between patients and their healthcare providers.

As Dr. Redberg said, “This small, increased risk of cardiovascular events means that one cannot make a general recommendation about stopping statins in this patient population. There should be shared decision-making between the patient and the healthcare professional to know if it is appropriate for an individual to discontinue the medication.”

For the average 77-year-old—the average age of the study participants—the findings serve as a reminder that medical status is dynamic. A treatment that was essential at younger ages may require a fresh look, but that look must be guided by the reality that while the risks of stopping are not immediate, they are not zero.

Worth a look